SPONSOR
argenx
Total Trials
3
Recruiting
3
Phases
Phase 2, Phase 3, Phase 1, Phase 2
Conditions studied: Immune Thrombocytopenia (ITP)ITP - Immune ThrombocytopeniaITPImmune Thrombocytopenic PurpuraImmune Thrombocytopenic Purpura ( ITP )Idiopathic Thrombocytopenic PurpuraIdiopathic Thrombocytopenic Purpura (ITP)Healthy VolunteersSystemic Sclerosis (SSc)
argenx is a clinical research sponsor with 3 registered studies on ClinicalTrials.gov, of which 3 are actively recruiting participants. Research covers conditions including Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia, ITP, Immune Thrombocytopenic Purpura.
The trial portfolio spans Phase 2, Phase 3, Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — argenx
How many clinical trials has argenx sponsored?
ClinicalMetric currently tracks 3 clinical trials sponsored by argenx, of which 3 are actively recruiting participants. These trials cover conditions including Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia, ITP. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does argenx research focus on?
argenx clinical trials span Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia, ITP, Immune Thrombocytopenic Purpura, Immune Thrombocytopenic Purpura ( ITP ), and additional conditions. The research pipeline includes Phase 2, Phase 3, Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a argenx clinical trial?
To participate in a argenx trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all argenx trials with current recruitment status updated daily.
Clinical Trials by argenx
NCT07194850 Phase 2, Phase 3
Recruiting
A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
Immune Thrombocytopenia (ITP)
NCT07612020 Phase 1
Recruiting
A Study to Assess the Absolute Bioavailability of Empasiprubart SC Administered With an Autoinjector and the Pharmacokinetic Noninferiority of Empasiprubart SC Versus Intravenous (IV) in Healthy Adult Participants
Healthy Volunteers
NCT06655155 Phase 2
Recruiting
A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
Systemic Sclerosis (SSc)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology